Abstract:Transcatheter aortic valve replacement (TAVR) has emerged as an alternative treatment for patients with pure severe aortic regurgitation (PSAR) who are contraindicated for surgery or have a high surgical risk. However, the therapeutic efficacy and safety of TAVR in low Society of Thoracic Surgeons score (STS) risk patients remain to be clarified. This study aimed to explore the feasibility of TAVR treatment in different STS risk patients and to compare the adverse events between the groups. In this study, patients with PSAR who underwent TAVR at Zhongshan Hospital, Fudan University, China, during the inclusion period were included and categorized into three groups based on STS scores. The baseline data, imaging results, and follow-up data of the patients were documented. As a result, out of 75 TAVR patients, 38 (50.7%) patients were categorized as low risk (STS<4) and 37 (49.3%) patients were categorized as intermediate- and high-risk (STS≥4). Compared with patients at intermediate- and high-risk, those in the low-risk group were younger, had a lower body mass index, had a lower prevalence of hypertension, chronic obstructive pulmonary disease, and prior PCI and had better cardiac function ( p all < 0.05). In the hospital and at the 1-month follow-up, the degree of AR and cardiac function were significantly improved. No significant difference was found between the two groups in the hospital or during the 30-day follow-up. In conclusion: TAVR for PSAR in low STS risk patients is safe and efficient during 30 days of follow-up compared with intermediate and high STS risk groups. TAVR for PSAR should not be limited to inoperable or STS-defined high-risk patients. Long-term follow-up is needed for further investigation.

Short-term Outcomes of Transcatheter Aortic Valve Replacement in Low-risk Patients with Pure Severe Aortic Regurgitation